# Drugs for Neglected Diseases initiative (DNDi)

Type: organization

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/drugs-for-neglected-diseases-initiative-dndi
Canonical HTML page: https://gethealthbrief.com/entity/drugs-for-neglected-diseases-initiative-dndi

## Timeline

- **2026**: Rollout Milestone — Acoziborole enters the final stages of regulatory rollout for endemic regions.
- **2022**: Trial Results — Phase 2/3 clinical trial results for Acoziborole show high efficacy.
- **2018**: Fexinidazole Approval — First all-oral 10-day treatment for sleeping sickness is approved.
- **2009**: Research Begins — DNDi starts screening compounds for a single-dose HAT treatment.

## Recent coverage (1 stories)

### Single-Dose Breakthrough: Acoziborole Signals End of Sleeping Sickness
2026-03-16 21:44:53 · Sentiment: Strongly positive · Impact: 8/10 · Sources: 2

The introduction of Acoziborole, a single-dose oral medication, marks a pivotal shift in the global fight against Human African Trypanosomiasis. This breakthrough treatment simplifies complex therapeutic regimens, potentially enabling the total elimination of the disease by 2030.
Full story: https://gethealthbrief.com/story/acoziborole-sleeping-sickness-elimination-2026

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.